European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.nuvaxovid xbb.1.5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccines - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4.2 and 5.1 in product information document).the use of this vaccine should be in accordance with official recommendations.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga lifescience sdn. bhd. - inactivated sars-cov-2 virus (cz02 strain) (vero cell) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga lifescience sdn. bhd. - inactivated sars-cov-2 virus (cz02 strain) (vero cell) -

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ad26.cov2.s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 8.92 log10 infectious units per dose) - suspension for injection - active: ad26.cov2.s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 8.92 log10 infectious units per dose) excipient: citric acid monohydrate ethanol hydrochloric acid hydroxypropyl-beta-cyclodextrin polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - covid-19 vaccine janssen has provisional consent for the indication below: active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

novavax, inc. - sars-cov-2 spike glycoprotein vaccine antigen nvx-cov2373 (unii: uk9ak2in1p) (sars-cov-2 spike glycoprotein vaccine antigen nvx-cov2373 - unii:uk9ak2in1p) - the u.s. food and drug administration (fda) has issued an emergency use authorization (eua) for the emergency use of novavax covid-19 vaccine, adjuvanted (2023-2024 formula) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 12 years of age and older. novavax covid-19 vaccine, adjuvanted is not licensed for any use. justification for emergency use of vaccines during the covid-19 pandemic there is currently an outbreak of covid-19 caused by sars-cov-2. the secretary of the department of health and human services (hhs) has: - determined that there is a public health emergency, or a significant potential for a public health emergency related to covid-19.4 - declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the covid-19 pandemic.5 an eua is an fda authorization for the emergency use of an unapproved product or unapproved use of an approved

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

duopharma (m) sdn. bhd. - inactivated sars-cov-2 virus (19ncov-cdc-tan-hb02 strain) (vero cell) -

European Union - English - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccines - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine

Kenya - English - Pharmacy and Poisons Board

inactivated sars-cov-2 virus (19ncov-cdc-tan-hb02… - injection - (1) 0.5ml/syringe (each pre-filled syringe… - covid-19 vaccines